USA flag logo/image

An Official Website of the United States Government

Targeting a Poor Prognosis Marker for Tumor Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95894
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA144614
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
ADVANCED TARGETING SYSTEMS, INC.
10451 Roselle St #300 SAN DIEGO, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Targeting a Poor Prognosis Marker for Tumor Therapy
Agency: HHS
Contract: 1R43CA144614-01A1
Award Amount: $150,480.00
 

Abstract:

DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the s urvival rate for many types of cancer has improved in recent years; however, it is still the second leading cause of death in the United States. This proposal describes an experimental design to verify the suitability of basigin-2 (also known as CD147 or E MMPRIN) as a cell surface target for an innovative tumor therapy. This project will accomplish important goals in determining the suitability of basigin-2 for further drug development: 1) Provide proof of internalization of the target moiety (basigin-2) b y using an antibody to basigin-2, and 2) Demonstrate that there is specificity, both in terms of greater ability to target the tumor over normal (lower level) expression and that anti-basigin is specific for the target. In this Phase I grant, a cytotoxin w ill be produced that has two components: 1) anti-basigin to specifically target and internalize into basigin-2 positive cells, and 2) a toxin that will inhibit protein synthesis upon internalization by the antibody. This innovative approach will create a m olecule that targets tumor cells, metastasis and angiogenesis, with the idea to not just slow tumor cell proliferation, but to eliminate tumors. PUBLIC HEALTH RELEVANCE: Targeting a Poor Prognosis Marker for Tumor Therapy Narrative This project begins a new direction of potential treatment for a wide range of deadly cancers by targeting a molecule that is expressed on the surface of many tumor types with poor prognosis. While it is proposed to directly target these tumors through targeting the m olecule, basigin-2, targeting of tumor metastasis and angiogenesis is also indicated, since basigin-2 plays important roles in those dangerous processes. The project builds on current technologies, but puts several together to go in a new, innovative direc tion.

Principal Investigator:

Douglas A. Lappi
8586421988
TARGETING@ATSBIO.COM

Business Contact:

Denise Higgins
ats@atsbio.com
Small Business Information at Submission:

ADVANCED TARGETING SYSTEMS, INC.
10451 Roselle St #300 SAN DIEGO, CA 92121

EIN/Tax ID: 133063225
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No